Bold Innovation. Extraordinary Science.

Transformative solutions for severe diseases

As a company rooted in creating solutions to improve the lives of people living with neurological and immunological conditions, we’ve made many scientific advances over the decades – innovations that have allowed people living with severe diseases to have better lives. We incorporate the individual experiences of patients and caregivers into the discovery, development, and delivery of our medicines, leveraging their insights to inform our science and develop innovative and differentiated solutions for specific patient populations, including rare patient populations, to provide a positive impact for patients and society.

u.s. research & development Global science

Patient-Science-Solution

The toughest challenges require ambitious science. Our unique Patient-Science-Solution Model emphasizes that our science must have an impact for patients, so we make medicines that are manufacturable and deliverable. This makes innovation a key part of everything we do by allowing researchers and scientists to see their work on molecules in a lab all the way through the process. It’s this approach that gives our teams the ability to uncover new ways to help those living with severe diseases.

Purpose-driven data and technology

We use cutting edge data and technology to explore scientific solutions, personalize treatments, accelerate development timelines, and improve the overall patient experience. These powerful tools are a part of our unique Digital Business Transformation, which helps us create both drug and non-drug solutions that transform scientific breakthroughs into health-changing treatments. 

Learn more about Digital Business Transformation 

The power of partnerships

Our pipeline spans rare disease, epilepsy and immunology, and we work tirelessly to provide value to patients across every part of their treatment and care journey, from developing innovative medicines to working with partners to create resources and awareness materials.

Diversity in clinical trials

We strive for our solutions to provide the best individual experience for patients, and we aim for our study participants to reflect the populations that will ultimately benefit from our new medicines. This means encompassing a broader spectrum of the population in clinical trials, ultimately advancing health for all patients and helping us better understand our investigational drugs and make better medicines.  We are committed to working toward a clinical trials infrastructure that promotes clinical trial diversity to better reflect the intended treatment population.  For more information on U.S. trials, including information on disease area, study type, location, contact information, and recruitment status, visit ClinicalTrials.gov.